Tumor mutation burden may predict outcomes from ADC in urothelial carcinoma
The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).
Several biomarkers may be associated with differential outcomes to enfortumab vedotin (Padcev) for the treatment of patients with advanced urothelial carcinoma, which may help inform clinical decision making, according to an analysis of the UNITE study.
Findings from the analysis were presented at the 2023 ASCO GU Cancers Symposium.
Enfortumab vedotin is an antibody drug conjugate that targets Nectin-4 and is widely used to treat patients with treatment-refractory advanced urothelial carcinoma. Despite its wide use in this patient population, data are limited regarding biomarkers to predict outcomes with this therapy.
Researchers analyzed data from the retrospective UNITE study, particularly of 170 patients (median age, 70; 78% men) from 16 sites with available next-generation sequencing. In addition, patients in this analysis were treated with enfortumab vedotin alone outside of a clinical trial setting.
Investigators observed response to enfortumab vedotin in patients with scans after 1 or more doses of the therapy. Several molecular biomarkers were assessed including tumor mutation burden, somatic alterations in at least 10% of patients, PD-L1 status and the presence of 1 or more DNA damage response mutations.
Other factors that were assessed in this study include median progression-free survival (PFS), overall response rates (ORRs), and overall survival (OS).
Of the patients in this study, 65% had pure urothelial histology, 69% had a primary bladder tumor, and 68% had 2 or more lines of therapy before receiving treatment with enfortumab vedotin.
The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).
Patients in the study had a median progression-free survival of 6 months and a median overall survival of 12 months. Shorter PFS times were observed in patients with CDKN2A (HR, 1.7; 95% CI, 1.1-2.8), CDKN2B (HR, 2; 95% CI, 1.2-3.4) and MTAP alterations (HR, 1.3; 95% CI, 0.7-2.6). Patients with high tumor mutation burden had longer median OS (HR, 0.4; 95% CI, 0.2-0.9).
“Upon external validation, these findings can help inform clinical decision making and potential therapy sequencing in patients with advanced urothelial carcinoma,” the researchers wrote in the abstract.
Reference:
Jindal T, Kilari D, Alhalabi O, et al. Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Presented at: 2023 ASCO GU Cancers Symposium; February 16-18, 2023; San Francisco. Abstract #450.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
